Patrick Trucchio, an analyst from H.C. Wainwright, has initiated a new Buy rating on Aligos Therapeutics (ALGS).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight the potential of Aligos Therapeutics’ lead candidate, ALG-000184, in transforming the treatment landscape for chronic hepatitis B virus (HBV). The drug has shown promising results as a capsid assembly modulator, achieving significant reductions in HBV DNA and key biomarkers, which positions it as a potential new standard-of-care for chronic HBV suppression. Its dual mechanism of action and strong pharmacokinetics distinguish it from existing treatments, offering broader antiviral effects and applicability across a wide range of patients.
Furthermore, Aligos Therapeutics is poised to create substantial value beyond HBV treatment with its pipeline, including ALG-055009, a thyroid hormone receptor-beta agonist with promising Phase 2a data in metabolic dysfunction-associated steatohepatitis (MASH). The company’s strategic positioning, coupled with multiple upcoming clinical milestones and potential partnerships, supports a positive outlook for its stock. With clear regulatory guidance and ongoing global trials, Aligos is well-positioned to redefine chronic HBV management and deliver long-term shareholder value.
ALGS’s price has also changed dramatically for the past six months – from $22.790 to $8.770, which is a -61.52% drop .